Trial purpose
Cancer treatment
Tumor type
Multi-Cancer
Age
18+
Clinical summary
Summary
Eligible participants will be allocated into treatment arms depending on their cancer type and prior treatment. All arms will receive treatment with both vidutolimod (intratumourally) and cemiplimab (intravenously).
The different treatment arms include:
- People with cutaneous squamous cell carcinoma (CSCC) who have not received prior systemic therapy for their CSCC;
- People with CSCC who have progressed while receiving a PD-1-blocking antibody or are within 12 weeks of discontinuation of treatment for CSCC;
- People with merkel cell carcinoma (MCC) who have not received prior systemic therapy for MCC;
- People with MCC who have progressed while receiving a PD-1-blocking antibody or are within 12 weeks of discontinuation of treatment for MCC;
- People with triple negative breast cancer (TNBC) who have not received prior therapy with immune checkpoint inhibitors (iCPIs) for TNBC;
- People with TNBC who have progressed while receiving a PD-1-blocking antibody or are within 12 weeks of discontinuation of treatment for TNBC;
- People with basal cell carcinoma (BCC) who have not received prior hedgehog pathway inhibitor therapy, nor prior therapy with (iCPIs), for metastatic or locally and/or regionally advanced unresectable BCC;
- People with advanced non-small cell lung cancer (NSCLC) (metastatic or locally advanced who are not candidates for definitive chemoradiation, nor candidates for surgical resection), whose tumors have high PD-L1 expression (TPS ≥50%, as determined by a CAP/CLIA or equivalently licensed lab), have not received prior anti-PD-1/programmed cell death ligand 1 (PD-L1) therapy, and are amenable to IT therapy for advanced NSCLC.
Conditions
This trial is treating patients with merkel cell carcinoma, cutaneous squamous cell carcinoma, basal cell carcinoma, triple negative breast cancer, and non-small cell lung cancer
Eligibility
Inclusion
Participants enrolled in the study must meet all of the following inclusion criteria to be eligible.
- Histopathologically-confirmed diagnosis of cancer, as defined by the protocol.
- Measurable disease, as defined by RECIST v1.1 and as defined in the protocol.
- Adequate organ function based on most recent laboratory values within 3 weeks before first dose of study treatment on Week 1 Day 1 (W1D1), as defined in the protocol.
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1 at Screening.
Exclusion
Participants presenting with any of the following will not qualify for entry into the study:
- Received radiation therapy (or other non-systemic therapy) within 2 weeks before first dose of study treatment on W1D1. Participants should have recovered (i.e. Grade ≤ 1 or at baseline) from radiation-related toxicities.
- Received systemic pharmacologic doses of corticosteroids > 10 mg/day prednisone within 30 days before first dose of study treatment on W1D1, as defined in the protocol.
- History of immune-mediated AE leading to permanent discontinuation due to prior PD-1-blocking antibody.
- Not fully recovered from AEs due to prior treatment (to Grade 1 or less, per Common Terminology Criteria for Adverse Events (CTCAE), with the exception of persistent vitiligo, alopecia, hypothyroidism, diabetes mellitus, and adrenal and/or pituitary insufficiency.
- Active pneumonitis or history of noninfectious pneumonitis that required steroids.
- Severe uncontrolled medical disease within 12 months of screening, including but not limited to poorly controlled hypertension, unstable angina, myocardial infarction, congestive heart failure (New York Heart Association Class II or greater), pericarditis, cerebrovascular accident, or implanted or continuous use of a pacemaker or defibrillator, or emphysema with FEV1 ≤ 50% predicted.
- Known history of immunodeficiency.
- Known additional malignancy that is progressing or required active treatment within the past 3 years, as defined in the protocol.
- Active autoimmune disease that required systemic treatment in past 2 years; replacement therapy is not considered a form of systemic treatment.
- Untreated, symptomatic, or enlarging central nervous system metastases or carcinomatous meningitis (including leptomeningeal metastases from solid tumors).
NOTE: Other protocol defined Inclusion/Exclusion Criteria apply
Inclusion
- Your cancer has spread to other parts of the body (metastatic) or has grown into nearby parts of the body (locally advanced).
- Your cancer has not spread to other parts of the body (localised).
Exclusion
- You have been diagnosed with a prior or secondary type of cancer.
- You have certain types of non-cancer medical conditions.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria, and other criteria may apply for this trial. Ask your doctor about whether this trial could be right for you.
More information
Trial Identifiers
Information on this page is partially produced from ClinicalTrials.gov *. View further details about this trial on the registry via the links below:
Trial sponsor
Regeneron Pharmaceuticals
Scientific Title
A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer
Get Support
You might find it helpful to speak to someone who has 'been there before'. Our Cancer Connect program can provide one-on-one phone support from someone who understands what you're going through and has clinical trials experience.
Know more about Cancer Connect
If you need cancer information and practical support for yourself, a carer, family or friend, contact Cancer Council’s experienced cancer nurses on 131120.
Get support
When you are considering a cancer clinical trial, it is a good idea to discuss it with your family, friends or carers.
More info for carers